BioCryst Pharmaceuticals (BCRX) Downgraded by BidaskClub to “Hold”

BioCryst Pharmaceuticals (NASDAQ:BCRX) was downgraded by analysts at BidaskClub from a “buy” rating to a “hold” rating in a research report issued on Tuesday.

A number of other brokerages have also issued reports on BCRX. JMP Securities lifted their target price on BioCryst Pharmaceuticals from $12.00 to $16.00 and gave the company an “outperform” rating in a research report on Wednesday, September 5th. HC Wainwright reaffirmed a “buy” rating and set a $13.00 target price on shares of BioCryst Pharmaceuticals in a research report on Monday, August 13th. They noted that the move was a valuation call. Seaport Global Securities reaffirmed a “neutral” rating on shares of BioCryst Pharmaceuticals in a research report on Thursday, June 28th. Zacks Investment Research raised BioCryst Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, July 10th. Finally, Jefferies Financial Group reaffirmed a “buy” rating and set a $8.50 target price on shares of BioCryst Pharmaceuticals in a research report on Thursday, August 9th. Five research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $9.57.

Shares of BCRX stock opened at $6.77 on Tuesday. BioCryst Pharmaceuticals has a 52-week low of $4.12 and a 52-week high of $8.13. The company has a debt-to-equity ratio of 0.35, a current ratio of 1.25 and a quick ratio of 1.25. The company has a market cap of $834.59 million, a P/E ratio of -8.68 and a beta of 1.64.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last issued its quarterly earnings results on Tuesday, August 7th. The biotechnology company reported ($0.19) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.24) by $0.05. BioCryst Pharmaceuticals had a negative return on equity of 107.85% and a negative net margin of 270.95%. The firm had revenue of $12.49 million during the quarter, compared to analyst estimates of $3.80 million. Research analysts expect that BioCryst Pharmaceuticals will post -0.86 EPS for the current year.

In other news, CMO William P. Sheridan sold 62,500 shares of the business’s stock in a transaction on Thursday, August 9th. The stock was sold at an average price of $7.03, for a total value of $439,375.00. Following the completion of the transaction, the chief marketing officer now directly owns 85,713 shares of the company’s stock, valued at approximately $602,562.39. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Thomas R. Staab II sold 9,850 shares of the business’s stock in a transaction on Wednesday, October 3rd. The stock was sold at an average price of $7.24, for a total value of $71,314.00. Following the completion of the transaction, the insider now directly owns 140,633 shares of the company’s stock, valued at $1,018,182.92. The disclosure for this sale can be found here. Insiders own 5.21% of the company’s stock.

Several institutional investors and hedge funds have recently added to or reduced their stakes in BCRX. Janus Henderson Group PLC raised its position in shares of BioCryst Pharmaceuticals by 45.0% in the 2nd quarter. Janus Henderson Group PLC now owns 11,096,183 shares of the biotechnology company’s stock worth $63,581,000 after acquiring an additional 3,441,498 shares in the last quarter. BlackRock Inc. raised its position in shares of BioCryst Pharmaceuticals by 3.8% in the 2nd quarter. BlackRock Inc. now owns 7,755,951 shares of the biotechnology company’s stock worth $44,442,000 after acquiring an additional 281,532 shares in the last quarter. VHCP Management II LLC raised its position in shares of BioCryst Pharmaceuticals by 11.0% in the 2nd quarter. VHCP Management II LLC now owns 2,464,241 shares of the biotechnology company’s stock worth $14,120,000 after acquiring an additional 243,270 shares in the last quarter. UBS Group AG raised its position in shares of BioCryst Pharmaceuticals by 190.7% in the 1st quarter. UBS Group AG now owns 291,379 shares of the biotechnology company’s stock worth $1,390,000 after acquiring an additional 191,157 shares in the last quarter. Finally, Rock Springs Capital Management LP raised its position in shares of BioCryst Pharmaceuticals by 13.8% in the 1st quarter. Rock Springs Capital Management LP now owns 925,000 shares of the biotechnology company’s stock worth $4,412,000 after acquiring an additional 112,500 shares in the last quarter. 80.23% of the stock is owned by hedge funds and other institutional investors.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, designs, optimizes, and develops small molecule drugs that block key enzymes involved in the pathogenesis of diseases. The company markets peramivir, an intravenous neuraminidase inhibitor, which is approved for uncomplicated seasonal and acute influenza in the United States and Canada under the name RAPIVAB, in Japan and Taiwan as RAPIACTA, and in Korea as PERAMIFLU; and Mundesine, an oral purine nucleoside phosphorylase inhibitor to treat cancer in Japan.

Featured Article: Why is insider trading harmful?

Analyst Recommendations for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply